Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijantimicag.2020.106103 http://scihub22266oqcxt.onion/10.1016/j.ijantimicag.2020.106103 32712333!7377685!32712333     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Antimicrob+Agents 2020 ; 56 (3): 106103 Nephropedia Template TP {{tp|p=32712333|t=2020. Tocilizumab for severe COVID-19: a systematic review and meta-analysis |pdf=|usr=}}{{32712333}} gab.com Text Tocilizumab for severe COVID-19: a systematic review and meta-analysis JO: Int J Antimicrob Agents http://www.kidney.de/pget.php?&tw=1&pmid=32712333 #FOAvip This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the treatment of severe coronavirus disease 2019 (COVID-19). Candidate studies up to 24 May 2020 were identified from PubMed, Cochrane Library, Embase, medRxiv and bioRxiv. Treatment outcomes included mortality, risk of intensive care unit (ICU) admission and the requirement for mechanical ventilation (MV). Seven retrospective studies involving 592 adult patients with severe COVID-19, including 240 in the tocilizumab group and 352 in the control group, were enrolled. All-cause mortality of severe COVID-19 patients among the tocilizumab group was 16.3% (39/240), which was lower than that in the control group (24.1%; 85/352). However, the difference did not reach statistical significance [risk ratio (RR) = 0.62, 95% confidence interval (CI) 0.31-1.22; I(2) = 68%]. Additionally, risk of ICU admission was similar between the tocilizumab and control groups (35.1% vs. 15.8%; RR = 1.51, 95% CI 0.33-6.78; I(2) = 86%). The requirement for MV was similar between the tocilizumab and control groups (32.4% vs. 28.6%; RR = 0.82, 95% CI 0.14-4.94; I(2) = 91%). However, these non-significant differences between the tocilizumab and control groups may have been the result of baseline characteristics of the tocilizumab group, which were more severe than those of the control group. Based on low-quality evidence, there is no conclusive evidence that tocilizumab would provide any additional benefit to patients with severe COVID-19. Therefore, further recommendation of tocilizumab for COVID-19 cases should be halted until high-quality evidence from randomised controlled trials is available. Twit Text FOAVip Tocilizumab for severe COVID-19: a systematic review and meta-analysis ????Int J Antimicrob Agents http://www.kidney.de/pget.php?&tw=1&pmid=32712333 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32712333 #FOAvip English Wikipedia <ref>{{Cite pmid|32712333}}</ref> Tocilizumab for severe COVID-19: a systematic review and meta-analysis #MMPMID32712333 Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR Int J Antimicrob Agents 2020[Sep]; 56 (3): 106103 PMID32712333show ga This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the treatment of severe coronavirus disease 2019 (COVID-19). Candidate studies up to 24 May 2020 were identified from PubMed, Cochrane Library, Embase, medRxiv and bioRxiv. Treatment outcomes included mortality, risk of intensive care unit (ICU) admission and the requirement for mechanical ventilation (MV). Seven retrospective studies involving 592 adult patients with severe COVID-19, including 240 in the tocilizumab group and 352 in the control group, were enrolled. All-cause mortality of severe COVID-19 patients among the tocilizumab group was 16.3% (39/240), which was lower than that in the control group (24.1%; 85/352). However, the difference did not reach statistical significance [risk ratio (RR) = 0.62, 95% confidence interval (CI) 0.31-1.22; I(2) = 68%]. Additionally, risk of ICU admission was similar between the tocilizumab and control groups (35.1% vs. 15.8%; RR = 1.51, 95% CI 0.33-6.78; I(2) = 86%). The requirement for MV was similar between the tocilizumab and control groups (32.4% vs. 28.6%; RR = 0.82, 95% CI 0.14-4.94; I(2) = 91%). However, these non-significant differences between the tocilizumab and control groups may have been the result of baseline characteristics of the tocilizumab group, which were more severe than those of the control group. Based on low-quality evidence, there is no conclusive evidence that tocilizumab would provide any additional benefit to patients with severe COVID-19. Therefore, further recommendation of tocilizumab for COVID-19 cases should be halted until high-quality evidence from randomised controlled trials is available. |Anti-Inflammatory Agents/*administration & dosage/adverse effects[MESH] |Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects[MESH] |Antiviral Agents/*administration & dosage/adverse effects[MESH] |Bacterial Infections/diagnosis/etiology/immunology/mortality[MESH] |Betacoronavirus/drug effects/growth & development/immunology[MESH] |COVID-19[MESH] |Coronavirus Infections/immunology/mortality/*therapy/virology[MESH] |Cytokine Release Syndrome/immunology/mortality/therapy/virology[MESH] |Cytokines/antagonists & inhibitors/genetics/immunology[MESH] |Drug Administration Schedule[MESH] |Humans[MESH] |Immunologic Factors/*administration & dosage/adverse effects[MESH] |Intensive Care Units[MESH] |Opportunistic Infections/diagnosis/etiology/immunology/mortality[MESH] |Pandemics[MESH] |Pneumonia, Viral/immunology/mortality/*therapy/virology[MESH] |Respiration, Artificial[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Survival Analysis[MESH]Tocilizumab for severe COVID-19: a systematic review and meta-analysis(epmc).pdf DeepDyve Pubget Overpricing